Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
about
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
P2860
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Nilotinib 300 mg twice daily: ...... nic myeloid leukemia patients.
@en
type
label
Nilotinib 300 mg twice daily: ...... nic myeloid leukemia patients.
@en
prefLabel
Nilotinib 300 mg twice daily: ...... nic myeloid leukemia patients.
@en
P2093
P2860
P50
P1433
P1476
Nilotinib 300 mg twice daily: ...... nic myeloid leukemia patients.
@en
P2093
Angelo Michele Carella
Elena Trabacchi
Gianni Binotto
Giuseppe Visani
Luciano Levato
Marco Gobbi
Mariella D'Adda
Marzia Salvucci
Michele Cavo
Paolo Avanzini
P2860
P304
P356
10.3324/HAEMATOL.2016.144949
P50
P577
2016-07-28T00:00:00Z